ENDEAVOR trial: Carfilzomib and dexamethasone for relapsed multiple myeloma

Jesús San Miguel

At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain, discusses the results of the multicenter, open-label, randomized, phase 3 ENDEAVOR trial of carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed multiple myeloma.

Share this video  
Multiple Myeloma
Bortezomib, Carfilzomib, Dexamethasone
EHA 2015
11th June 2015
More from Jesús San Miguel
Phase 2 study of daratumumab monotherapy for heavily pretreated and refractory multiple myeloma
Frontline treatment of elderly multiple myeloma patients and management of relapse/refractory
Highlights from the 2016 European Multiple Myeloma Academy (EMMA) and overview of EMMA 2017
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals